Soluble HLA Class I and Class II Molecule Levels in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients

[1]  J. Kesselring,et al.  Frontiers in Multiple Sclerosis , 1998 .

[2]  M. Krönke,et al.  Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes , 1996, Nature Medicine.

[3]  N. Tsuchiya,et al.  Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus. , 1996, Arthritis and rheumatism.

[4]  J. Antel,et al.  Myelin basic protein and human coronavirus 229E cross‐reactive T cells in multiple sclerosis , 1996, Annals of neurology.

[5]  F. Barkhof,et al.  Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis , 1996, Annals of neurology.

[6]  J. Frederiksen,et al.  Acute optic neuritis: Myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system , 1995, Annals of neurology.

[7]  G. Filaci,et al.  Increased serum concentration of soluble HLA-DR antigens in HIV infection and following transplantation. , 1995, Tissue antigens.

[8]  Jingwu Z. Zhang,et al.  Clonal expansion of myelin basic protein‐reactive T cells in patients with multiple sclerosis: Restricted T cell receptor V gene rearrangements and CDR3 sequence , 1995, European journal of immunology.

[9]  S. Ferrone,et al.  Serum HLA class I antigens: markers and modulators of an immune response? , 1995, Immunology today.

[10]  M. Marrosu,et al.  Genetic susceptibility to multiple sclerosis , 1994, Annals of neurology.

[11]  A. Sadovnick,et al.  Genetic epidemiology of multiple sclerosis: A survey , 1994, Annals of neurology.

[12]  A. Sette,et al.  T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans , 1994, Journal of Neuroimmunology.

[13]  S. Ferrone,et al.  Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. , 1994, Human immunology.

[14]  A. Nocera,et al.  HLA class-I-soluble antigen serum levels in liver transplantation. A predictor marker of acute rejection. , 1994, Human immunology.

[15]  D. Hafler,et al.  Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. , 1994, Journal of immunology.

[16]  D. Ferguson,et al.  Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes. , 1994, Journal of Clinical Investigation.

[17]  Norbert,et al.  Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. , 1993, The Journal of clinical investigation.

[18]  S. Ferrone,et al.  Summary report from the first international workshop on soluble HLA antigens. Paris, August 1992. , 1993, Tissue antigens.

[19]  N. Zavazava,et al.  Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. , 1993, Tissue antigens.

[20]  C. Marboe,et al.  Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. , 1993, Journal of immunological methods.

[21]  I. Catz,et al.  Autoantibodies to myelin basic protein within multiple sclerosis central nervous system tissue , 1993, Journal of the Neurological Sciences.

[22]  R. Hughes.  Pathogenesis of multiple sclerosis. , 1992, Journal of the Royal Society of Medicine.

[23]  H. Tilg,et al.  Soluble HLA class I serum concentrations increase with transplant-related complications after liver transplantation. , 1992, Journal of hepatology.

[24]  F. Thinnes,et al.  Quantitation of Soluble HLA Class II Molecules by an Enzyme‐Linked Immunosorbent Assay , 1991, Vox sanguinis.

[25]  H. Link,et al.  Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls , 1991, Journal of Neuroimmunology.

[26]  L. Kappos,et al.  Myelin basic protein‐specific T lymphocyte lines from MS patients and healthy individuals , 1990, Neurology.

[27]  L. Villar,et al.  Soluble Class 1 antigens (sHLA) in CSF and serum of patients with HIV infection , 1990, Acta neurologica Scandinavica.

[28]  J. Seidman,et al.  Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. , 1990, Science.

[29]  H. Grosse-wilde,et al.  Soluble HLA class I concentrations and GVHD after allogeneic marrow transplantation. , 1989, Transplantation.

[30]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[31]  S. Ferrone,et al.  HETEROGENEOUS DISTRIBUTION OF THE DETERMINANTS DEFINED BY MONOCLONAL ANTIBODIES ON HLA‐A AND B ANTIGENS BEARING MOLECULES , 1982, Transplantation.

[32]  V. Quaranta,et al.  Characterization of the specificity of DR monoclonal antibodies. , 1979, Transplantation proceedings.

[33]  C. Barnstable,et al.  Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. , 1979, Journal of immunology.

[34]  S. Ferrone,et al.  Production and characterization of DR xenoantisera: use for detection of serum DR antigens. , 1979, Journal of immunology.